The study took advantage of a powerful experimental approach: generating motor neurons from induced pluripotent stem cells (iPSCs) derived from patients with FUS-ALS. These cells carry the same genetic mutation found in patients, allowing researchers to study the disease in a human cellular context rather than relying solely on animal models. Crucially, the team developed methods to separate the cell bodies from the axons of these motor neurons, enabling them to examine gene expression and RNA regulation in each compartment independently. This compartment-specific analysis revealed something unexpected: even in healthy human motor neurons, different regions of the cell use different versions of the 3′ untranslated region (3’UTR)—the portion of messenger RNA that controls protein production and localization. When the researchers compared healthy and FUS-ALS motor neurons, they found that this compartment-specific 3’UTR regulation was disrupted in the disease state, affecting genes such as SNCA, which has previously been implicated in other neurodegenerative conditions including Parkinson’s disease.

Among all the molecular changes the team detected, one stood out for its consistency and magnitude: SLITRK2, a gene encoding a protein normally involved in neuronal development and synapse formation, was strongly and repeatedly upregulated across multiple independent FUS-ALS models. This was not a chance finding in a single cell line or experimental condition; the elevation appeared reliably whenever the researchers examined motor neurons carrying FUS mutations. The consistency of this signal suggested that SLITRK2 might not simply be a bystander in the disease process but could be actively contributing to the axonal and synaptic defects that characterize early FUS-ALS pathology.

To test this hypothesis directly, the researchers used a genetic silencing technique to reduce SLITRK2 expression in the FUS-ALS motor neurons. The results were striking: lowering SLITRK2 levels normalized the axonal defects that had been observed in the diseased neurons. Axons, which in ALS patients begin to degenerate long before muscle weakness becomes apparent, showed measurable improvement when this single gene was suppressed. This finding positions SLITRK2 as a potential therapeutic target—something that could be modulated to slow or prevent the earliest stages of motor neuron decline in this form of ALS.

But axonal health is only part of the story. Motor neurons must ultimately communicate with muscle fibers through specialized connections called neuromuscular junctions, and it is the failure of these junctions that directly produces the muscle weakness and atrophy seen in ALS patients. To investigate whether SLITRK2 reduction could also rescue functional deficits at these connections, the team developed a sophisticated experimental system: a fully iPSC-derived neuromuscular junction model grown in microfluidic chips. These tiny devices compartmentalize motor neurons and muscle cells in separate chambers connected by narrow channels, allowing axons to grow toward the muscle and form functional synapses while keeping the two cell types physically separated. This setup mimics key aspects of the in vivo neuromuscular architecture and enables precise measurement of synaptic transmission.

Using this neuromuscular junction-on-a-chip system, the researchers made a nuanced discovery. When they reduced SLITRK2 in FUS-ALS motor neurons, the signaling between nerve and muscle was significantly rescued—the junctions transmitted electrical and chemical signals more effectively, approaching the levels seen in healthy connections. However, this functional improvement occurred without any change in the physical innervation of the muscle: the number and extent of nerve-muscle contacts remained the same. Additionally, the treatment did not correct the hypo-excitability of the motor neurons themselves—the reduced ability of these cells to fire electrical impulses that is another hallmark of FUS-ALS. This dissociation between functional rescue and structural or excitability correction provides important insight into the disease mechanism: SLITRK2 appears to specifically regulate the synaptic signaling machinery rather than the overall architecture of the neuromuscular junction or the intrinsic electrical properties of the motor neuron.

This selectivity is scientifically significant because it suggests that different aspects of ALS pathology—axonal degeneration, synaptic dysfunction, and altered neuronal excitability—may be driven by partially independent molecular pathways. A therapeutic strategy targeting SLITRK2 could therefore address some symptoms of the disease without necessarily correcting all of them, which has implications for how such treatments might be combined with other approaches in the future. It also underscores the value of the compartment-specific and functional assays the team developed: by measuring axonal morphology, synaptic transmission, and neuronal excitability separately, researchers can begin to disentangle the complex web of cellular defects that contribute to motor neuron loss.

Beyond the SLITRK2 finding itself, the study makes several broader contributions to ALS research. The detailed mapping of compartment-specific 3’UTR expression in human motor neurons provides a reference dataset that other researchers can use to investigate RNA regulation in both healthy and diseased states. The identification of altered 3’UTR isoforms in genes like SNCA across different cellular compartments suggests that RNA processing defects may be a common thread connecting multiple forms of neurodegeneration, not just FUS-ALS. And the fully iPSC-derived neuromuscular junction-on-a-chip model represents a robust new tool for the field—one that can be used to test potential therapeutics in a human-relevant system before moving to animal studies or clinical trials, potentially accelerating the drug development pipeline for this devastating disease.

The work was supported by funding from Stichting ALS Nederland through several collaborative projects, the European research consortia MAXOMOD and INTEGRALS, the ALS CURE project, Alzheimer Nederland, the EU Joint Programme for Neurodegenerative Diseases, Health-Holland, the Netherlands Organization for Scientific Research, the Research Foundation-Flanders, and the Muscular Dystrophy Association. The research team included contributors from the University Medical Center Utrecht Brain Center, the VIB-KU Leuven Center for Neuroscience, Utrecht University, and Erasmus MC University Medical Center in Rotterdam. The corresponding author, R. Jeroen Pasterkamp, led the study from the Department of Translational Neuroscience in Utrecht.

While the findings are promising, they represent an early step in a long translational journey. The experiments were conducted in laboratory-grown human cells, and translating these results into treatments for patients will require extensive further research, including validation in animal models and eventually clinical testing. Nevertheless, the identification of SLITRK2 as a driver of axonal and synaptic deficits in FUS-ALS provides researchers with a concrete molecular target and a clearer picture of how this form of ALS begins its destructive course. As the field continues to unravel the complex biology of motor neuron degeneration, studies like this one—combining human stem cell models, compartment-specific molecular analysis, and functional neuromuscular junction assays—are helping to build the foundation for future therapies that might one day slow, halt, or even reverse the progression of ALS.

Subject of Research: SLITRK2 regulation of axonal and neuromuscular junction deficits in FUS-ALS motor neurons

Article Title: SLITRK2 knockdown rescues axonal and functional neuromuscular junction deficits in human iPSC-derived mutant FUS-ALS motor neurons

Article References: de Jongh, R., Wiersema, A. F., van Dijk, C. H., Verdegaal, R. C., Smulders, M. M. J., Basak, O., van Os, J., Peeters, S., Olmedo-Martínez, L., Bloemenkamp, L. M., Garner, K. M., Da Cruz, S., Koppers, M., Iuliano, A., Pijnappel, W. W. M. P., Kenna, K. P., & Pasterkamp, R. J. (2026). SLITRK2 knockdown rescues axonal and functional neuromuscular junction deficits in human iPSC-derived mutant FUS-ALS motor neurons. Nature Communications. https://doi.org/10.1038/s41467-026-78419-7

Image Credits: AI Generated

DOI: 10.1038/s41467-026-78419-7

Keywords: ALS, FUS, SLITRK2, motor neurons, iPSC, neuromuscular junction, axons, 3'UTR, SNCA, neurodegeneration, microfluidics, synaptic signaling

The panel itself is ambitious in scope. The researchers assembled 564 gene loci linked to Parkinson’s disease, repeat expansion disorders, and other neurodegenerative movement disorders, drawing on established diagnostic panels from the genomics company CeGaT, the International Parkinson and Movement Disorder Society Taskforce, 90 Parkinson’s disease genome-wide association study loci, and the catalog of known repeat expansion genes. Each gene locus was padded with 50 kilobases of flanking sequence on either side, and the mitochondrial genome was added as a separate target. Together the target regions span roughly 113.6 million base pairs, or about 3.44 percent of the GRCh38 human reference genome, comfortably within the 1 to 5 percent fraction recommended for optimal enrichment with adaptive sampling.

The sequencing strategy relies on Oxford Nanopore Technologies’ adaptive sampling, a clever real-time filtering technique built into the MinKNOW operating software. As DNA molecules thread through the protein nanopores, the software maps the first few hundred bases of each read against a predefined BED file of target coordinates. Reads that align to the panel’s genes continue to be sequenced in full, while off-target molecules are ejected from the pore, freeing it to capture another molecule. The result is targeted enrichment without any wet-lab capture step, preserving the native DNA and its long read lengths. In this study, three patient samples were multiplexed per PromethION flow cell and sequenced for 72 hours using R10.4.1 flow cells and super-accuracy base calling with the Dorado basecaller.

The performance metrics are respectable for a first demonstration. Across 18 individuals, the panel achieved a mean on-target coverage of 24X per sample, with a standard deviation of 9X, and a mean on-target read N50 of 21.5 kilobases, a read-length metric considered suitable for detecting structural variants. The average Phred quality score was 19.7. Coverage varied considerably across loci, partly because some genes sit in notoriously difficult genomic terrain: several panel genes lie within or near the highly polymorphic major histocompatibility complex on chromosome 6, and 20 of the 31 genes with mean coverage below 15X are X-linked and therefore less abundant in the ten male participants. The mitochondrial genome, by contrast, reached a mean depth of 1256X.

To test diagnostic utility, the team sequenced 15 positive controls with previously characterized pathogenic variants and 3 negative controls with idiopathic Parkinson’s disease or frontotemporal dementia. The positive controls spanned the full variant spectrum: single-nucleotide variants and small indels in GBA1, LRRK2, PRKN, and RAB32; large deletions in PRKN ranging from 20 to 320 kilobases; a 1.7-megabase triplication encompassing the entire SNCA gene; and repeat expansions in ATXN1, ATXN2, ATXN3, HTT, DAB1, FGF14, C9orf72, and the TAF1-SVA retrotransposon insertion that causes X-linked dystonia-parkinsonism. Of the 20 expected pathogenic variants, 17 were clearly identified, a detection rate of 85 percent with a Clopper-Pearson 95 percent confidence interval of 62 to 97 percent.

The small-variant results were flawless. The EPI2ME human variation workflow, which chains together Minimap2 alignment, the Clair3 deep-learning variant caller, the Sniffles2 structural variant caller, and the Straglr repeat caller, correctly detected all six known single-nucleotide variants and small indels, including the LRRK2 p.G2019S mutation and three PRKN variants. This success reflects years of improvement in nanopore base-calling accuracy, with Q-scores above 20 now routine using R10 chemistry. Structural variants proved harder. Sniffles2 with default parameters caught two large PRKN deletions but missed three others, and no caller detected the SNCA triplication. However, the alternative callers CuteSV and SVIM, run with adjusted size parameters, recovered two of the missed deletions, and visual inspection in the Integrative Genomics Viewer confirmed all PRKN deletions, enabling the team to establish compound heterozygosity through read-based phasing with WhatsHap. The SNCA triplication left a telltale signature even without a formal call: coverage over the SNCA locus was 2.5-fold higher than the panel average, a hint that dedicated copy-number tools for targeted data could convert into a definitive diagnosis.

Repeat expansions showed a mixed picture. Straglr correctly identified pathogenic expansions in ATXN1, ATXN2, ATXN3, and HTT, with repeat numbers closely matching prior results, and the independent Noise Cancelling Repeat Finder tool confirmed them with deviations of only a few repeat units. Expansions in DAB1 and FGF14 were missed by the workflow version of Straglr simply because those genes are absent from its reference catalog, but a standalone version with a custom input file, together with NCRF, detected both. The two failures are instructive. The C9orf72 hexanucleotide expansion, whose GC-rich repeats can form G-quadruplex structures, yielded only six expanded reads despite 43X coverage, too few and too variable to assign a reliable repeat number. The TAF1-SVA insertion is absent from the GRCh38 reference genome entirely, so adaptive sampling discarded some relevant reads as off-target, and the gene’s X-chromosome location further reduced coverage in male samples, leaving only three informative reads. Both cases were classified as inconclusive rather than false negatives, and the authors suggest that reducing the target fraction or increasing coverage could resolve them.

Beyond confirming known variants, the panel surfaced five additional findings in five patients that had not been previously reported for those individuals: potentially pathogenic variants in STXBP2, AP4S1, RARS2, and ALS2, and a CCTG repeat expansion of 137 units in CNBP, the gene associated with myotonic dystrophy type 2. All were validated by Sanger sequencing or PCR and gel electrophoresis. Notably, none of the affected patients showed clinical features of the corresponding conditions, which are mostly recessive, so the team interprets these as incidental findings demanding cautious counseling rather than new diagnoses. Intriguingly, 13 patients also carried benign AAAAG expansions in RFC1, below the pathogenic threshold of 250 repeats, illustrating how comprehensively long reads expose the repetitive landscape of the genome.

The economics are part of the appeal. With three samples multiplexed per flow cell, the sequencing cost per patient, roughly 330 to 830 euros, matches a whole-genome nanopore run for a single individual, and validation steps would bring the total to roughly 500 to 1000 euros as a first-line test. Because the panel is defined by a simple text file of genomic coordinates, it can be updated overnight as new Parkinson’s risk loci and repeat motifs are discovered. The authors envision it as either a first-line combined test ordered by an experienced clinician or a second-line assay after negative short-read sequencing. Limitations remain real: the cohort was small, four samples came from induced pluripotent stem cells rather than blood, which is unsuitable for clinical diagnostics because reprogramming can introduce somatic variants, and most variant callers are still optimized for whole-genome rather than targeted long-read data. Manual inspection of difficult variants, about 30 minutes per sample, is not scalable. Still, as specialized tools mature and larger validation cohorts accumulate, the vision of a single, flexible, cost-effective test that reads out point mutations, massive rearrangements, and sprawling repeat expansions in one pass is coming sharply into focus.

Subject of Research: A targeted long-read nanopore sequencing gene panel for the combined genetic diagnosis of Parkinson's disease and repeat expansion disorders

Article Title: Unified long-read panel for Parkinson’s and repeat expansion disorders

Article References: Fienemann, A., Prietzsche, J. C., Laβ, J., Much, C., Schaake, S., Lüth, T., Gabbert, C., Zimprich, A., Stögmann, E., König, T., Ganos, C., Gül-Demirkale, T., Başak, A. N., Jamora, R. D. G., Rosales, R. L., Saranza, G., Diesta, C. C. E., Möller, M., Borsche, M., … Trinh, J. (2026). Unified long-read panel for Parkinson’s and repeat expansion disorders. npj Parkinson's Disease, 12(1), Article 233. https://doi.org/10.1038/s41531-026-01585-4

Image Credits: AI Generated

DOI: 10.1038/s41531-026-01585-4

Keywords: Parkinson's disease, long-read sequencing, Oxford Nanopore, adaptive sampling, repeat expansion disorders, genetic diagnostics, structural variants, LRRK2, PRKN, SNCA, C9orf72, gene panel

The molecular process at the heart of the study is called alternative polyadenylation, or APA. When a gene is transcribed into messenger RNA, the transcript’s 3-prime untranslated region, or 3-prime UTR, is trimmed and capped with a polyadenylated tail at one of several possible positions. Which cleavage site the cell chooses matters enormously: the sequence, length and structure of the 3-prime UTR determine where the mRNA travels inside the cell, how stable it is, and how efficiently it is translated into protein. In neurons, which must deliver specific mRNAs to distant dendrites and synapses, this choice is especially consequential. Yet until now, APA in the human brain had never been mapped at single-cell resolution, and its genetic control remained largely unknown.

The team mined an extraordinary resource: single-nucleus RNA sequencing data from 379 postmortem human brains, part of the Religious Orders Study and Rush Memory and Aging Project, spanning roughly two million cells across seven major brain cell types, including excitatory and inhibitory neurons, astrocytes, oligodendrocytes, oligodendrocyte progenitor cells, microglia and vascular cells. Because 3-prime-biased sequencing directly captures the polyadenylation sites of detected transcripts, the researchers could identify more than 30,000 unique cleavage sites and quantify, for each gene in each cell type in each individual, the relative usage of proximal versus distal polyadenylation sites, an index known as PDUI.

The atlas immediately revealed striking cell-type signatures. Neurons, on average, carry significantly longer 3-prime UTRs than other brain cells, while microglia carry shorter ones, and these differences persisted even among genes expressed broadly across all cell types, suggesting they arise from the global regulatory environment of each cell rather than from which genes are expressed there. The team also predicted 374 RNA-binding proteins and transcription factors whose expression tracks 3-prime UTR length across individuals, including known polyadenylation regulators such as PABPN1 and CPSF7 as well as candidates like ZNF460 and EHMT2. Knockdown experiments in SH-SY5Y-derived neurons validated several of these regulators, with U2AF2, PCBP2 and PABPN1 each controlling hundreds of reproducible APA targets.

When the researchers compared individuals across the spectrum of Alzheimer’s disease, they found that APA changes were widespread but largely invisible to conventional expression analysis. More than 3,000 genes showed differential polyadenylation in late-stage Alzheimer’s, concentrated in neurons, yet the vast majority of these genes showed no change in expression at all. Genes with altered 3-prime UTR usage in neurons were enriched for pathways central to Alzheimer’s biology, including microglial activation, microtubule transport, axodendritic transport and mitochondrial function, and included established risk genes such as MAPT, ABCA7 and MEF2C. In other words, APA acts as an independent, largely orthogonal layer of dysregulation that converges on the same disease pathways through a different set of genes.

The study then connected APA to genetics by integrating the atlas with whole-genome sequencing, identifying 3-prime UTR quantitative trait loci, or 3-prime aQTLs, for 4,288 genes. These are genetic variants that bias which polyadenylation site a gene uses. The team validated two such variants, at the DHX34 and DNAJA1 loci, using CRISPR-based prime editing in HEK293T cells, finding strong correlations between editing frequency and polyadenylation usage. Notably, the aQTLs colocalized far more often with protein quantitative trait loci than with expression QTLs, implying that many of these variants act on translation or protein abundance rather than on mRNA levels, a mechanism that expression-based studies structurally cannot detect.

The disease implications are substantial. Across 17 brain traits and diseases, the researchers linked 168 genome-wide association study loci to 3-prime aQTLs, and only about 17.5 percent of these were shared with eQTLs. In Alzheimer’s disease, the PLEKHA1 and APOC2 loci showed aQTL-dependent associations; in schizophrenia, PAK6 and AP3B2; in bipolar disorder, NDUFA13; and the MTCH2 locus, associated with multiple brain traits, appears to alter protein output through stop-codon readthrough controlled by 3-prime UTR choice. Particularly striking was the APOC2 finding: a microglial aQTL within the APOE locus remained genome-wide significant even after conditioning on eight independent variants, and had no effect on APOC2 expression, marking it as an APOE-independent, expression-independent contribution to Alzheimer’s risk.

Perhaps the most dramatic result concerns Parkinson’s disease. The top Parkinson’s risk locus, near the SNCA gene that encodes alpha-synuclein, colocalized strongly with a neuronal and oligodendrocyte aQTL. By dissecting SNCA’s 3-prime UTR into four distinct polyadenylation sites, the team showed that the risk variant rs356220 promotes usage of the most proximal site, with little to no effect on total SNCA expression. Imaging experiments told the biological story: the short pA1 isoform preferentially localized to neurites, while longer isoforms remained more abundant in the cell body, and individuals with Parkinson’s disease showed increased proximal SNCA 3-prime UTR usage in excitatory neurons. The risk allele’s effect direction matched the disease-associated shift, suggesting the locus acts by rerouting SNCA mRNA within neurons rather than by changing how much of it is made.

The authors are candid about limitations. Sparse single-nucleus data introduce technical noise, statistical power was limited for some non-neuronal cell types, and further experiments are needed to distinguish direct from secondary regulator effects. But the broader message is hard to overstate: a post-transcriptional regulatory layer that is essentially free to measure from existing 3-prime-biased single-cell datasets explains a meaningful slice of brain disease heritability that expression analyses miss entirely. The researchers propose that APA profiling should become a standard complementary modality in future single-cell studies, and that 3-prime UTR-targeted therapeutics, informed by cell-type-specific aQTL maps, represent a promising new frontier for treating Alzheimer’s, Parkinson’s and other devastating neurological disorders.

Subject of Research: Single-cell mapping of alternative polyadenylation and its genetic regulation in the human brain and its role in neurodegenerative and neuropsychiatric disease

Article Title: Single-cell profiling and genetic regulation of alternative polyadenylation in the human brain

Article References: Nan, J., Boix, C. A., Shi, S., Fan, X., Ni, J., Wang, K., Shuai, X., Ding, K., Wu, P., An, Y., Sun, N., Hou, L., Chen, K., Huang, X., Li, C., Akay, L., Louderback, K., Nawaid, H., Park, Y. P., … Xiong, X. (2026). Single-cell profiling and genetic regulation of alternative polyadenylation in the human brain. Nature Genetics. https://doi.org/10.1038/s41588-026-02758-w

Image Credits: AI Generated

DOI: 10.1038/s41588-026-02758-w

Keywords: alternative polyadenylation, 3' UTR, single-cell RNA sequencing, Alzheimer's disease, Parkinson's disease, SNCA, 3'aQTL, GWAS, gene regulation, neurons, microglia, post-transcriptional regulation

The researchers, led by Caoimhe Morley and Christos Proukakis, built on their earlier finding that somatic copy number gains of SNCA, the gene encoding alpha-synuclein, occur in the brains of people with synucleinopathies. In their new study, published in Acta Neuropathologica, they asked whether these gains arise specifically in oligodendrocytes, whether they cluster in the brain regions most damaged by the disease, and whether they correlate with the pathological inclusions that define it. Their strategy hinged on a technically demanding hybrid method that combines fluorescent in situ hybridisation, or FISH, with immunofluorescence, applied not to tissue sections but to suspensions of individual nuclei isolated from fresh-frozen post-mortem brain tissue.

The methodological choice matters. Working on sections makes it nearly impossible to reliably detect copy number losses, because slicing the tissue can truncate FISH signals and mimic a missing gene copy. Isolating nuclei eliminates this artefact while preserving alpha-synuclein inclusions, which in multiple system atrophy often sit in perinuclear or nuclear positions and remain attached to the nuclei during preparation. Each nucleus could therefore be interrogated on several axes simultaneously: the number of SNCA copies it carried, whether it belonged to the oligodendrocyte lineage as marked by the transcription factor SOX10, and whether it harboured an alpha-synuclein inclusion. The team analysed tissue from the putamen, cerebellum and substantia nigra of 13 cases with the striatonigral degeneration subtype, 12 cases with the olivopontocerebellar atrophy subtype, and 15 controls from the Queen Square Brain Bank.

The results were striking. Somatic SNCA copy number variants, both gains and losses, were significantly more frequent in multiple system atrophy oligodendrocytes than in controls. Gains were enriched more than threefold, appearing in 6.3 percent of SOX10-positive oligodendrocytes compared with 2.0 percent in controls, while losses were present in 12.5 percent versus 7.4 percent, with both differences highly significant. Crucially, the gains were not randomly distributed. They concentrated in the regions preferentially devastated by each disease subtype: the putamen in striatonigral degeneration and the cerebellum in olivopontocerebellar atrophy, along with the substantia nigra in both. The analysis also showed that CNVs were preferentially enriched at the SNCA locus itself; a chromosome 7 reference probe displayed relative genomic stability, indicating a locus-specific phenomenon rather than wholesale genomic chaos.

The single-cell correlations provide the study’s most provocative evidence. In the preferentially affected region of each subtype, oligodendrocytes carrying a somatic SNCA gain were more than twice as likely to contain an alpha-synuclein inclusion as their neighbours with a normal copy number, an effect that vanished in less affected regions. At the regional level, the frequency of oligodendrocyte gains correlated significantly with the overall burden of glial inclusions. This dovetails with established biology: people who inherit extra copies of SNCA develop parkinsonism driven by chronic alpha-synuclein overproduction, with duplications causing later-onset disease and triplications causing aggressive early-onset forms. Mouse models engineered to overexpress human alpha-synuclein specifically in oligodendrocytes develop inclusion-like pathology, demyelination and neuroinflammation. The new data suggest that the same dosage logic operates cell by cell in the human disease brain, with gains locally pushing intracellular alpha-synuclein toward the aggregation threshold.

Perhaps the most clinically resonant finding is a correlation between copy number gain burden and disease onset. Cases carrying a higher average proportion of oligodendrocyte SNCA gains developed symptoms significantly earlier, with a Spearman correlation coefficient of minus 0.45 and a p-value of 0.03. No such relationship existed for gains in non-oligodendroglial cells or for losses. Moreover, within individual cases, the level of gains correlated across brain regions and between oligodendrocytes and other cell populations, hinting that some patients carry an intrinsic, case-wide propensity for SNCA mosaicism. This raises the possibility of an early clonal event, arising during development, that seeds descendant cells across multiple regions and predisposes the brain to alpha-synuclein aggregation decades later. Distinguishing this from a generalised susceptibility to SNCA instability will require deep single-cell whole-genome sequencing, which is only now approaching the necessary resolution.

The study also reported, for the first time in multiple system atrophy, somatic SNCA losses. These were elevated in both oligodendrocytes and other cells but told a different story. They showed no clear regional predilection matching each subtype’s pathology, associated with inclusions only in the substantia nigra, and showed no correlation with age of onset or disease duration. That pattern argues against a primary causal role. Unlike gains, germline losses of SNCA have never been linked to synucleinopathies, and mice lacking alpha-synuclein do not develop relevant neurodegenerative phenotypes. The authors instead propose that losses may arise secondarily as the disease progresses, through the mis-repair of DNA damage.

That hypothesis gains weight from the study’s final arm, an examination of DNA double-strand breaks using immunofluorescence for gamma H2AX, the phosphorylated histone that marks sites of breakage and repair. Across the sampled regions, the proportion of gamma H2AX-positive cells was significantly higher in multiple system atrophy than in controls, 4.9 versus 2.5 percent overall, and nearly fourfold higher within oligodendrocytes. The signal was stronger in the preferentially affected regions and, strikingly, present in 22.2 percent of inclusion-bearing cells versus 14.9 percent of inclusion-free ones. This mirrors recent reports in Lewy body diseases linking DNA damage to alpha-synuclein pathology. Because post-mitotic brain cells repair double-strand breaks through the error-prone non-homologous end joining pathway, unrepaired or mis-repaired breaks can generate deletions, potentially including SNCA itself. Yet the authors caution that more than three-quarters of inclusion-positive cells showed no evidence of breaks, and the temporal sequence of damage, aggregation and copy number change remains unresolved.

The findings do not paint copy number variation as a sole cause. Most inclusion-bearing oligodendrocytes carried a normal SNCA copy number, and individuals with inherited SNCA multiplications typically develop a Parkinson-like picture rather than full multiple system atrophy, suggesting that somatic gains act as one influential contributor among many, a first hit or modifier that lowers the threshold for aggregation within vulnerable glia. Cell-type-specific stress, environmental exposures, unidentified inherited variants and other somatic mutations, possibly including age-related clonal haematopoiesis recently associated with the disease, are likely to complete the picture. Even so, the work reframes the search for multiple system atrophy’s origins. The culprit may not lie in the genome everyone inherits, but in the mosaic of genomes that individual brain cells acquire across a lifetime, and in oligodendrocytes silently accumulating extra copies of the very gene whose protein will one day fill them with inclusions.

Subject of Research: Somatic SNCA copy number variation in oligodendrocytes and its role in multiple system atrophy pathogenesis

Article Title: Oligodendroglial somatic SNCA copy number gains are associated with inclusions and disease onset in multiple system atrophy

Article References: Oligodendroglial somatic SNCA copy number gains are associated with inclusions and disease onset in multiple system atrophy. (n.d.). https://doi.org/10.1007/s00401-026-03077-4

Image Credits: AI Generated

DOI: 10.1007/s00401-026-03077-4

Keywords: multiple system atrophy, SNCA, alpha-synuclein, oligodendrocytes, somatic copy number variants, glial cytoplasmic inclusions, DNA double-strand breaks, gamma H2AX, fluorescent in situ hybridisation, genetic mosaicism, synucleinopathy, neurodegeneration